Moorfields hospital in London is the world's first dedicated clinic for the disorder and seven out of eight patients given ...

A new study demonstrates the effectiveness of a widely-used eye injection to manage the previously untreatable rare condition ...

Seven different postoperative complications occurred two to four times more often in patients who had a history of intravitreal drug injections as compared with those who did not. Among complications ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

People with a condition called wet age-related macular degeneration (AMD) often receive eye injections. These eye injections can help to improve vision and also stop the damage that causes vision to ...

People with proliferative diabetic retinopathy may develop another eye condition called macular edema. The macula is the part of the retina that processes the images in the center of your vision ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...